Psoriatic nail disease: Quality of life and treatment

Journal of Cutaneous Medicine and Surgery

Volumn 13, Issue SUPPL. 2, 2009, Pages

  Gupta, Aditya K ^a,c   Cooper, Elizabeth A ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; CYCLOSPORIN; DITHRANOL; ETANERCEPT; ETRETIN; FLUOROURACIL; INFLIXIMAB; METHOTREXATE; PLACEBO; TRIAMCINOLONE ACETONIDE;

ABSENCE OF SIDE EFFECTS; ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; ERYTHEMA; HUMAN; HYPERKERATOSIS; NAIL DISEASE; NAIL DYSTROPHY; NAIL PSORIASIS; ONYCHOLYSIS; OUTCOME ASSESSMENT; PARONYCHIA; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; QUALITY OF LIFE; SKIN ABRASION;

BIOLOGICAL FACTORS; HUMANS; NAIL DISEASES; PSORIASIS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 70449379640     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2009.00027     Document Type: Article

References (25)

1. Weiss SC, Kimball AB, Liewehr DJ, et al. Quantifying the harmful effects of psoriasis on health-related quality of life. J Am Acad Dermatol 2002;47:512-8.
2. Katugampola RP, Hongbo Y, Finlay AY. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. Br J Dermatol 2005; 152:1256-62.
3. Callen JP, Krueger GG, Lebwohl M, et al; American Academy of Dermatology. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 2003;49:897-9.
4. Smith CH, Anstey AV, Barker JN, et al; British Association of Dermatologists. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005;153:486-97.
5. Mayeaux EJ Jr. Nail disorders. Prim Care 2000; 27:333-51.
6. de Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1728 patients. Dermatology 1996;193:300-3.
7. Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: a prospective clinical study. J Cutan Med Surg 2003; 7:317-21.
8. Rich P, Griffiths CE, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008;58:224-31.
9. Eastmond CJ, Wright V. The nail dystrophy of psoriatic arthritis. Ann Rheum Dis 1979;38:226-8.
10. Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis - clinically important, potentially treatable and often overlooked. Rheumatology (Oxford) 2004;43:790-4.
11. Lavaroni G, Kokelj F, Pauluzzi P, et al. The nails in psoriatic arthritis. Acta Derm Venereol Suppl (Stockh) 1994; 186:113.
12. de Berker D. Management of nail psoriasis. Clin Exp Dermatol 2000;25:357-62.
13. Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007;57:1-27.
14. Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease. A systematic review. J Rheumatol 2006;33:1452-6.
15. van den Bosch F, Reece R, Behrens F, et al. Clinically important nail psoriasis improvements are achieved with adalimumab (Humira®): results from a large open-label prospective study (STEREO) [EULAR abstract FRI0472]. Ann Rheum Dis 2007;66 Suppl II:421.
16. Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:206-12.
17. Cassetty CT, Alexis AF, Shupack JL, et al. Alefacept in the treatment of psoriatic nail disease: a small case series. J Am Acad Dermatol 2005;52:1101-2.
18. Körver JE, Langewouters AM, Van De Kerkhof PC, et al. Therapeutic effects of a 12-week course of alefacept on nail psoriasis. J Eur Acad Dermatol Venereol 2006;20:1252-5.
19. Rich P, Gupta A, Wang A, et al. Etanercept improves nail psoriasis [AAD abstract P2751]. J Am Acad Dermatol 2005;52 Suppl 1:184.
20. Bianchi L, Bergamin A, de Felice C, et al. Remission and time to resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol 2005;52:736-7.
21. Rigopoulos D, Gregoriou S, Stratigos A, et al. Evaluation of the efficacy and safety on infliximab on psoriatic nails: an unblinded, non-randomized, open-label study. Br J Dermatol 2008;159:453-6.
22. Reich K, Nestle FO, Papp K, et al; EXPRESS Study Investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74.
23. Aktan S, Ilknur T, Akin C, et al. Interobserver reliability of the Nail Psoriasis Severity Index. Clin Exp Dermatol 2007;32:141-4.
24. Kaçar N, Ergin S, Erdoǧan BS. The comparison of Nail Psoriasis Severity Index with a less time-consuming qualitative system. J Eur Acad Dermatol Venereol 2008; 22:219-22.
25. Parrish CA, Sobera JO, Robbins CM, et al. Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol 2006;5:339-40.